Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 5/20 | 1.00 |
| ▸ | CHRNG | P07510 | 5/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 5/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 5/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRND | Q07001 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL30679332 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL12499296 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL38777 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL300444 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL5608195 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL636116 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL4972526 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL31748783 | 0.98 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6591 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250262160-A1 | COMPOSITIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2025-08-21 | — | — | US | claimed |
| EP-4511009-A1 | COMPOSITIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2025-02-26 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-119212685-A | Compositions for modified release of active ingredients | 普罗列维生物公司 | 2024-12-27 | — | — | CN | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| WO-2024118797-A1 | TREHALOSE FOR TREATING HUNTINGTON'S DISEASE | SEELOS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024088808-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2024-05-02 | — | — | WO | claimed |
| US-6197827-B1 | Nicotine addiction treatment | CARY MEDICAL CORPORATION | 2001-03-06 | — | — | US | claimed |
| WO-2001012175-A1 | USES COMPOSITIONS FOR TREATING OR PREVENTING SLEEP DISTURBANCES USING VERY LOW DOSES OF CYCLOBENZAPRINE | VELA PHARMACEUTICALS INC. (US) | 2001-02-22 | — | — | WO | claimed |
| CN-1280505-A | Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug | CARY MEDICAL CORP (US) | 2001-01-17 | — | — | CN | claimed |
| US-6150420-A | BY ADMINISTERING BUPROPRION OR SALT AND CARRIER INTRANASALLY; TREATING NICOTINE ADDICTION, DEPRESSION | THERAMAX, INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-1019088-A1 | COMPOSITION FOR THE TREATMENT OF NICOTINE ADDICTION CONTAINING A NICOTINE RECEPTOR ANTAGONIST AND AN ANTI-DEPRESSANT OR ANTI-ANXIETY DRUG | Cary Medical Corporation (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1011671-A1 | SUBSTANCE DEPENDENCE TREATMENT USING OPIATE ANTAGONISTS AND SEROTONIN COMPOUNDS | Yale University (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1999017803-A1 | COMPOSITON FOR THE TREATMENT OF NICOTINE ADDICTION CONTAINING A NICOTINE RECEPTOR ANTAGONIST AND AN ANTI-DEPRESSANT OR ANTI-ANXIETY DRUG | CARY MEDICAL CORPORATION (US) | 1999-04-15 | — | — | WO | claimed |
| WO-1998052565-A1 | SUBSTANCE DEPENDENCE TREATMENT USING OPIATE ANTAGONISTS AND SEROTONIN COMPOUNDS | YALE UNIVERSITY (US) | 1998-11-26 | — | — | WO | claimed |
| US-5486362-A | Controlled, sustained release delivery system for treating drug dependency | DYNAGEN, INC. (US) | 1996-01-23 | — | — | US | claimed |
| WO-1992019226-A1 | A CONTROLLED, SUSTAINED RELEASE DELIVERY SYSTEM FOR TREATING DRUG DEPENDENCY | DYNAGEN, INC. (US) | 1992-11-12 | — | — | WO | claimed |